Literature DB >> 1861059

Midazolam use in the emergency department.

E A Ramoska1, R Linkenheimer, C Glasgow.   

Abstract

Midazolam is a new imidazobenzodiazepine derivative that is two to three times as potent as diazepam, is water-soluble, has a rapid onset and short duration of action, and produces a profound amnestic effect. These properties make it an extremely useful drug for outpatient sedation. We performed retrospective review of midazolam use in a general emergency department over a one-year period. Midazolam was used in 120 patients, 71 men and 49 women, with an average age of 46 years. The average dose given was 3.4 mg, with a range of 1 to 10 mg. In 69 of the cases (57%) other drugs were administered, most commonly an opiate. There were only four adverse reactions. One patient developed urinary retention, one patient vomited, and two patients were somnolent for a prolonged period of time. There were no serious cardiovascular or respiratory problems. We conclude that midazolam is a safe drug to use in the emergency department. Close monitoring of the patient and the availability of airway support equipment are mandatory.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1861059     DOI: 10.1016/0736-4679(91)90421-b

Source DB:  PubMed          Journal:  J Emerg Med        ISSN: 0736-4679            Impact factor:   1.484


  5 in total

Review 1.  Pharmacological management of pain and anxiety during emergency procedures in children.

Authors:  R M Kennedy; J D Luhmann
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

Review 2.  Sedation and anesthesia for CT: emerging issues for providing high-quality care.

Authors:  Charles G Macias; Corrie E Chumpitazi
Journal:  Pediatr Radiol       Date:  2011-08-17

Review 3.  Emergency department management of pain and anxiety related to orthopedic fracture care: a guide to analgesic techniques and procedural sedation in children.

Authors:  Robert M Kennedy; Jan D Luhmann; Scott J Luhmann
Journal:  Paediatr Drugs       Date:  2004       Impact factor: 3.022

4.  Midazolam premedication for Ketamine-induced emergence phenomenon: A prospective observational study.

Authors:  Deepa Kameswari Perumal; Mangaiarkkarasi Adhimoolam; Nitya Selvaraj; Suneeth Pullikotil Lazarus; Meher Ali Raja Mohammed
Journal:  J Res Pharm Pract       Date:  2015 Apr-Jun

5.  Nasal and buccal treatment of midazolam in epileptic seizures in pediatrics.

Authors:  Ayşe Ulgey; Recep Aksu; Cihangir Bicer
Journal:  Clin Med Insights Pediatr       Date:  2012-07-24
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.